RxDoctor Payments Data

Devaguptapu Rao, MD

Vascular Surgery · Newark, DENPI 1235142142

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,164 of the $4,476 with a category attached, or 70.7%. 19 manufacturers reported payments, led by Endologix LLC at 33.2% of the total. Reporting peaked in 2023 at $1,601 and has fallen 95.3% since, to $75 in 2025.

$4,476in general payments, 2019–2025

Across 121 payments — averaging $36.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$1K
  • Boston Scientific$935
  • Medtronic$650
  • Inari Medical, Inc.$292
  • Terumo Medical Corporation$277
  • W. L. Gore & Associates, Inc.$168
  • plus $666 from 13 others

What the payments were for

  • Travel & lodging$1,31229%
  • Food & beverage$3,16471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,186,831
Medicare patients
1,141
Services billed
4,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$66,884
XareltoRivaroxaban53$64,962
ClopidogrelClopidogrel Bisulfate364$4,612
Cilostazol52$2,052
Penicillin V Potassium16$668
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$567
Doxycycline Hyclate22$402
Atorvastatin Calcium13$365
Gabapentin14$331
Simvastatin12$141
Furosemide12$69
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$49
Prednisone15$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$66,88456 claims
Johnson & JohnsonXarelto$35$64,96253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular surgery providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other vascular surgery in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →